Antipyretic TRIZ Cases

Cytokine-primed chondrocytes regenerate hyaline cartilage, reducing injection frequency and systemic side effects.

A topical analgesic composition merges cannabis compounds with salicylates and counter-irritants to enhance skin penetration.

A thermosensitive poloxamer gel transitions from liquid to viscous state at body temperature for targeted periodontal pocket delivery.

Boron-containing compounds inhibit Janus kinase activity, reducing adverse effects associated with topical corticosteroids in autoimmune disease treatment.

DPH1.1 monoclonal antibody targets HMGB1 residues 48-78 to inhibit chemoattractant activity and reduce inflammatory cell recruitment.

Defined bacterial compositions repair epithelial barriers and modulate cytokine production, resolving side effects from immune modulation therapies.

Optimizing the fed to fasted ratio of AUC and Cmax for Compound 1 reduces cardiovascular adverse events and shortens titration periods.

Optimizing ziltivekimab dosage schedules reduces cardiovascular morbidity while maintaining neutrophil counts to avoid infection risk.

HDAC inhibitors reactivate viral thymidine kinase to enable antiviral drugs against latent Epstein-Barr virus.

A liquid adalimumab composition uses citrate buffering and sugar stabilizers to maintain protein integrity under stress conditions.

A humanized anti-BLyS antibody targets B lymphocyte stimulating factor to inhibit B cell proliferation.

Undecylenic acid stabilizers protect menthol activity in liquid-filled gum, preventing degradation during shelf life.

Replacing radiation-based imaging with epigenetic nucleosome analysis in sputum improves clinical accuracy while eliminating patient exposure to harmful X-rays.

Optimized anti-IL36R antibodies reduce immunogenicity while maintaining binding affinity for treating psoriasis and ulcerative colitis.

Soluble epoxide hydrolase inhibitor stabilizes epoxyeicosatrienoic acids to reduce pain and inflammation in horses.

Systemic monoterpenes improve inhaled respiratory therapeutic activity, reducing required doses and side effects for bronchopulmonary disorders.

Small hydrophilic drug molecules enter pain-sensing neurons through activated receptors to block voltage-gated ion channels.

Exemestane activates the Keap1-Nrf2 pathway to upregulate phase 2 cytoprotective proteins, addressing oxidative stress in non-mammary tumors.

Targeting the Exon-21 periostin isoform resolves chronic inflammation treatment trade-offs by delivering specific inhibition without systemic side effects.

Topical cannabinoid nanolipids enhance active ingredient delivery through the stratum corneum barrier to improve pain relief effectiveness.

An anti-IL1RAP antibody binds the common receptor accessory protein to block inflammatory and fibrotic processes.

Merges antioxidant catechins with anti-inflammatory lipids to inhibit cytokine activity, reducing cartilage degradation in degenerative joint disease.

Replacing methionine with glutathione and ethanedithiol prevents oxidation-induced aggregation in tocilizumab liquid pharmaceutical compositions.

Supercritical CO2 extraction paired with macroporous resin adsorption isolates flavones, saponins, and organic acids from herbal powders.

Bispecific antibodies bind distinct DR5 epitopes to overcome TRAIL short half-life and enhance apoptosis in resistant tumors.

An antibody molecule binds the IL-17BR receptor to block IL-25 bioactivity.

Segmenting active substances into distinct tablet layers prevents incompatibility and segregation risks while preserving sensitive polymer coatings.

A STAT3-specific antibody fused with a cell-penetrating peptide enables nuclear delivery of the therapeutic molecule.

Chitin nanofibers carrying vitronectin support adherent cell suspension culture with stirring.

Graphene acupoint patches improve adhesion and analgesic effects by increasing drug release rates to treat dysmenorrhea.

Anti-S100A4 antibodies extract the S100A4 mediator from the tumour-stroma system to overcome therapeutic resistance and inhibit metastasis.

Engineered bacterial cells produce chondroitin and heparosan with controlled size homogeneity, eliminating depolymerization steps.

N434H mutation extends canine IgG half-life from 9 to 17 days, reducing dosing frequency and adverse events.

Gel formulations increase plasma cannabinoid concentration, reducing dosage costs while maintaining therapeutic efficacy.

BIA compounds inhibit BI-1 binding to mTORC2, suppressing AKT activity to reduce tumor size while avoiding chemotherapy side effects.

Oxygen-depleted blood storage reduces oxidative stress and hemolysis during extended preservation periods.

Cyclodextrin inclusion complexes and methionine antioxidant protection reduce antibody precipitation in high-concentration liquid pharmaceuticals.

Panaxadiol glycoside derivatives reduce systemic side effects while maintaining potent anti-inflammatory efficacy for asthma and COPD treatment.

Modified clinoptilolite removes cesium ions from the body via ion exchange, preventing radiation damage.

Antrodia cinnamomea extract lowers ACE-2 expression to address inadequate viral binding prevention in current treatments.

Asymmetric Fc variant modifications eliminate random homodimer assembly, resolving the trade-off between manufacturing complexity and binding specificity.

SKI606 targets RANK signaling to prevent bone destruction in metastatic cancer.

MEDI6570 targets LOX-1 to reduce non-calcified plaque volume, addressing unmanaged inflammation in standard cardiovascular care.

Blocking CYP1A2 enzymes with fluvoxamine prevents mebendazole metabolism, resolving low bioavailability and improving anti-proliferative efficacy.

Monoclonal antibodies bind CLDN18.2 to destroy cancer cells while sparing normal gastric epithelial tissues.

GM-CSF receptor antibody blocks pathological signaling to halt osteoarthritis progression beyond symptom management.